Catalyst Pharmaceuticals/ US14888U1016 /
| 2024-04-24 9:59:59 PM | Chg. +0.39 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 15.12USD | +2.65% | 17,961 Turnover: 270,941.40 |
-Bid Size: - | -Ask Size: - | 15.15 | 14.74 |
GlobeNewswire
04-22
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
GlobeNewswire
03-28
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS...
GlobeNewswire
03-27
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
GlobeNewswire
03-27
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority R...
GlobeNewswire
03-14
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
GlobeNewswire
03-13
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment...
GlobeNewswire
03-05
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference
GlobeNewswire
02-29
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Prov...
GlobeNewswire
02-27
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for ...
GlobeNewswire
02-21
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (A...
GlobeNewswire
02-14
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 2...
GlobeNewswire
02-14
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) ...
GlobeNewswire
01-15
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Mus...
GlobeNewswire
01-12
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy ...
GlobeNewswire
01-05
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
GlobeNewswire
01-04
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
GlobeNewswire
2023-12-18
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo...
GlobeNewswire
2023-12-18
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscul...
GlobeNewswire
2023-12-07
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage
GlobeNewswire
2023-12-05
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successf...
GlobeNewswire
2023-12-04
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Oth...
GlobeNewswire
2023-11-16
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference
GlobeNewswire
2023-11-08
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire
2023-11-02
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®
